In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of ...

Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Q32 Bio (QTTB – Research Report) today and set a price target of $20.00.

Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Oppenheimer slashed its price target on the stock to $20 from $80, but maintained the stock at Outperform. This comes after ...

Equities researchers at BMO Capital Markets began coverage on shares of Q32 Bio (NASDAQ:QTTB – Get Free Report) in a research note issued on Friday, Marketbeat Ratings reports. The brokerage set an ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the ...

Short interest in Q32 Bio Inc (NASDAQ:QTTB) increased during the last reporting period, rising from 678.64K to 686.07K. This put -% of the company's publicly available shares short. Short interest ...

US clinical-stage biotech Q32 Bio (Nasdaq: QTTB) saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed ...